The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.

Grzegorz CharlińskiNorbert GrzaskoArtur JurczyszynMariusz JanczarskiAgnieszka SzeremetAnna Waszczuk-GajdaPaweł BernatowiczAlina SwiderskaRenata Guzicka-KazimierczakEwa Lech-MarandaAndrzej SzczepaniakRyszard WicharyAnna Dmoszynska

Published in: European journal of haematology (2018)

This real-world data have confirmed that pomalidomide is an active drug in RRMM and support results of published clinical trials and other real-world studies.

Keyphrases

multiple myeloma
clinical trial
electronic health record
emergency department
randomized controlled trial
big data
systematic review
diffuse large b cell lymphoma
case control
artificial intelligence
adverse drug
data analysis